Cue Biopharma, Inc. (CUE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 19, 2025, by Cue Biopharma, Inc., a Delaware corporation. The filing discloses the entry into a material definitive agreement for an underwritten public offering of common stock, pre-funded warrants, and common stock warrants. The offering is expected to close on or about December 22, 2025.
Key Financial Metrics and Offering Details
The filing details a capital raise structured as follows:
- Securities Offered: 12,500,000 Firm Shares and 23,214,286 Pre-Funded Warrants, each accompanied by warrants to purchase common stock.
- Offering Price: $0.28 per Firm Share (plus warrant) and $0.279 per Pre-Funded Warrant (plus warrant).
- Estimated Net Proceeds: Approximately $8.9 million from the base offering. If the underwriters exercise their option in full, proceeds could reach approximately $10.3 million.
- Underwriting Option: Underwriters have a 30-day option to purchase up to 5,357,140 additional shares and/or warrants.
- Warrant Terms: Common stock warrants have an exercise price of $0.30 and a five-year term. Pre-funded warrants have an exercise price of $0.001.
The filing does not provide specific revenue, profit, or historical cash flow figures for the current period, as this is a transactional report rather than a periodic financial statement.
Material Changes and Liquidity Outlook
The primary material change is the execution of the underwriting agreement to secure immediate capital. Regarding liquidity and runway:
- Cash Runway: Management estimates that the net proceeds from this offering, combined with existing cash, cash equivalents, marketable securities, and $10.0 million in collaboration payments from ImmunoScape Pte. Ltd. ($5.0 million upfront received and $5.0 million time-based payment due in December 2025), will fund operations into the first quarter of 2027.
- Going Concern: The filing references the company's history of losses and its need to remediate a "going concern" determination regarding its ability to continue operations beyond the next twelve months without this financing.
Guidance, Risks, and Contingencies
Management commentary focuses on the extension of the cash runway to support research and development. Key risks and contingencies identified include:
- Closing Conditions: The offering is subject to customary closing conditions.
- Forward-Looking Uncertainty: The cash runway estimate is based on assumptions that may prove incorrect; capital resources could be consumed sooner than expected.
- Operational Risks: Risks include limited operating history, reliance on collaborators, potential setbacks in preclinical studies or clinical trials, and the inability to achieve profitability.
- Ownership Limits: Warrants and pre-funded warrants include beneficial ownership limitations (4.99% or 9.99% caps) to prevent excessive concentration of voting power.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds once the transaction settles (expected ~Dec 22, 2025).
- Confirm the receipt of the $5.0 million time-based payment from ImmunoScape Pte. Ltd. in December 2025.
- Monitor the exercise of the underwriters' 30-day option for additional shares.
- Review the company's most recent Form 10-K or 10-Q for detailed historical financials and the specific "going concern" disclosure referenced in the risk factors.
- Track the dilution impact of the 12.5 million shares, 23.2 million pre-funded warrants, and associated common stock warrants on existing shareholders.